Acute Ischemic Stroke

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins prior to ischemic stroke onset had significantly greater early cerebral reperfusion within 6 hours compared to patients not taking statins, with a 2-3-fold difference across all

Effect: improvement; median relative reperfusion 50% (IQR 30%,56%) vs 13% (IQR=5%,36%), p=0.014

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028